In addition to targeting the CD47/SIRPα axis, the pharmacological inhibition of BACE1 (β-site amyloid precursor protein-cleaving enzyme 1) using the inhibitor MK-8931 enhances TAM-mediated phagocytosis and hinders GBM progression in vivo [37]. Here, BACE1 is linked to glioblastoma.